title: Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration.
abstract: Background Unpredictable drug concentrations may lead to suboptimal exposure to nucleoside reverse transcriptase inhibitors (NRTIs) due to inadequate doses administered during continuous veno-venous hemofiltration (CVVH), which in turn may lead to decreased antiretroviral efficacy and possibly further HIV disease progression. Objective To compare administered doses of NRTIs to calculated doses of NRTIs to evaluate if patients were expected to have a favorable pharmacokinetic exposure profile while receiving CVVH. Methods The NRTI dose was compared to a table of recommendations based on a mathematical formula that estimates the amount of drug expected to be removed during CVVH. Results Twelve patients were on 27 NRTIs. Eleven (41%) NRTI doses were expected to provide a favorable pharmacokinetic profile based on pharmacokinetic mathematical calculations. Conclusion The majority of NRTIs were potentially not optimally dosed based on proposed pharmacokinetic calculations.
authors.affiliation: Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, 555 31st Street, Downers Grove, IL, 60515, USA. milgriff@nm.org.|Northwestern Memorial Hospital, 251 E Huron St., Chicago, IL, 60611, USA. milgriff@nm.org.
authors.forename: Milena M
authors.identifier: http://orcid.org/0000-0002-8748-185X
authors.initials: MM
authors.lastname: McLaughlin
authors.affiliation: Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, 555 31st Street, Downers Grove, IL, 60515, USA.
authors.forename: Inela
authors.initials: I
authors.lastname: Masic
authors.affiliation: Northwestern Memorial Hospital, 251 E Huron St., Chicago, IL, 60611, USA.
authors.forename: Lana
authors.initials: L
authors.lastname: Gerzenshtein
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D006440:Hemofiltration / Q000009:adverse effects / Q000639:trends*; D006801:Humans; D007902:Length of Stay / Q000639:trends; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*
chemical_list: D018894:Reverse Transcriptase Inhibitors
keywords: Continuous veno-vous hemofiltration; HIV; NRTIs; Nucleoside reverse transcriptase inhibitor; Pharmacokinetics